Cytek Biosciences (NASDAQ:CTKB – Get Free Report) and Quantum-Si (NASDAQ:QSI – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, valuation, analyst recommendations, profitability and risk.
Valuation & Earnings
This table compares Cytek Biosciences and Quantum-Si”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cytek Biosciences | $201.49 million | 3.03 | -$66.54 million | ($0.62) | -7.58 |
| Quantum-Si | $2.44 million | 68.73 | -$101.34 million | ($0.46) | -1.67 |
Volatility & Risk
Cytek Biosciences has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500. Comparatively, Quantum-Si has a beta of 3.24, suggesting that its share price is 224% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for Cytek Biosciences and Quantum-Si, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cytek Biosciences | 1 | 2 | 3 | 0 | 2.33 |
| Quantum-Si | 1 | 1 | 1 | 0 | 2.00 |
Cytek Biosciences presently has a consensus target price of $5.56, suggesting a potential upside of 18.35%. Quantum-Si has a consensus target price of $1.00, suggesting a potential upside of 29.85%. Given Quantum-Si’s higher possible upside, analysts clearly believe Quantum-Si is more favorable than Cytek Biosciences.
Profitability
This table compares Cytek Biosciences and Quantum-Si’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cytek Biosciences | -38.98% | -12.40% | -9.17% |
| Quantum-Si | -6,138.26% | -47.12% | -43.18% |
Institutional and Insider Ownership
69.5% of Cytek Biosciences shares are held by institutional investors. Comparatively, 39.9% of Quantum-Si shares are held by institutional investors. 10.4% of Cytek Biosciences shares are held by company insiders. Comparatively, 22.0% of Quantum-Si shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
Cytek Biosciences beats Quantum-Si on 8 of the 14 factors compared between the two stocks.
About Cytek Biosciences
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
About Quantum-Si
Quantum-Si incorporated, a life sciences company, engages in the development of single-molecule detection platform to enable Next Generation Protein Sequencing (NGPS). The company's platform is comprised of the Platinum NGPS instrument; the Platinum Analysis Software service; and reagent kits and semiconductor chips for use with its instruments. It is used in protein identification, protein variants, antibody characterization, biomarker identification, and post translational modification analysis applications. The company was founded in 2013 is headquartered in Branford, Connecticut.
Receive News & Ratings for Cytek Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytek Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
